<DOC>
	<DOCNO>NCT00003671</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child newly diagnose acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether delayed multidrug intensification give conjunction methotrexate leucovorin calcium rescue consolidation therapy child average risk acute lymphocytic leukemia . II . Determine feasibility deliver 6 course therapy patient . OUTLINE : This multicenter study . Induction : Patients receive oral dexamethasone twice daily day 1-29 , vincristine IV day 1 , 8 , 15 , 22 , asparaginase intramuscularly ( IM ) day 2 , 5 , 8 , 12 , 15 , 19 . Patients receive methotrexate intrathecally ( IT ) day 1 15 . CNS 2 3 patient also receive methotrexate IT day 8 22 . Patients M1 bone marrow receive oral mercaptopurine daily begin day 29 . Patients M2 bone marrow day 29 receive oral dexamethasone twice daily day 29-42 , vincristine IV daunorubicin IV 15 minute day 29 36 , asparaginase IM day 29 , 32 , 36 , 39 . Patients M3 bone marrow day 29 M2 M3 bone marrow day 43 take study . Consolidation : Patients receive methotrexate IV 4 hour week week 7 , 10 , 13 , 24 , 27 , 30 , oral leucovorin calcium every 6 hour 5 dos begin 42 hour start methotrexate infusion , methotrexate IT week 5 , 9 , 12 , 16 , 20 , 21 , 29 , asparaginase IM 3 time weekly week 16 17 , oral mercaptopurine daily week 5-14 week 24 end consolidation . Patients receive oral dexamethasone twice daily week 8 , 16-18 , 28 , vincristine IV day 1 week 8 , 9 , 16 , 17 , 18 , 28 , 29 , daunorubicin IV day 1 week 16 , 17 , 18 , cyclophosphamide IV 30 minute day 1 week 20 , cytarabine IV subcutaneously day 2-5 week 20 21 , oral thioguanine daily week 20 21 . Intensive continuation : Patients receive oral methotrexate every 6 hour 24 hour week 1 , 3 , 5 , 7 , oral mercaptopurine daily , oral leucovorin calcium every 12 hour 1 day begin 48 hour start oral methotrexate . Patients also receive methotrexate IT week 8 , vincristine IV day 1 week 8 , oral dexamethasone twice daily 7 day begin vincristine . Treatment repeat every 8 week 6 course . Another continuation : Patients receive oral methotrexate weekly except week methotrexate IT administration , oral mercaptopurine daily , methotrexate IT every 8 week , vincristine IV day 1 week 8 , oral dexamethasone twice daily 7 day begin vincristine . Treatment continue 130 week absence disease progression unacceptable toxicity . Patients follow every 6 month 4 year annually ten year . PROJECTED ACCRUAL : A total 50 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically newly diagnose early Bcell Bprecursor Bprogenitor acute lymphocytic leukemia Prior registration POG9400 , stratum 6 induction therapy Average prognosis ( neither good poor ) PATIENT CHARACTERISTICS : Age : Children Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior therapy POG9400</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>